Dichlorphenamide
Keveyis (dichlorphenamide) is a small molecule pharmaceutical. Dichlorphenamide was first approved as Daranide on 1982-01-01. It is used to treat glaucoma in the USA. It is known to target carbonic anhydrase 1, carbonic anhydrase 12, and carbonic anhydrase 4.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Keveyis (generic drugs available since 2022-12-29, discontinued: Daranide)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dichlorphenamide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KEVEYIS | Xeris Biopharma Holdings | N-011366 RX | 2015-08-07 | 1 products, RLD, RS |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dichlorphenamide | NDA authorized generic | 2023-03-10 |
| keveyis | New Drug Application | 2021-12-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| glaucoma | EFO_0000516 | D005901 | H40 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
17 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Congenital abnormalities | D000013 | EFO_0003915 | Q89.9 | — | — | — | 1 | — | 1 |
| Gastroschisis | D020139 | EFO_1000949 | Q79.3 | — | — | — | 1 | — | 1 |
| Meconium ileus | D000074270 | P76.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infertility | D007246 | EFO_0000545 | — | — | 1 | — | — | 1 | |
| Urethral stricture | D014525 | HP_0012227 | N35 | — | — | 1 | — | — | 1 |
| Colonic neoplasms | D003110 | C18 | — | — | 1 | — | — | 1 | |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | 1 | — | — | 1 | |
| Colonic polyps | D003111 | K63.5 | — | — | 1 | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intestinal obstruction | D007415 | K56.60 | — | — | — | — | 1 | 1 | |
| Colorectal neoplasms | D015179 | — | — | — | — | 1 | 1 | ||
| Gallstones | D042882 | EFO_0004210 | — | — | — | — | 1 | 1 | |
| Cholecystitis | D002764 | HP_0001082 | K81 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DICHLORPHENAMIDE |
| INN | diclofenamide |
| Description | Diclofenamide is a sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma. It has a role as an EC 4.2.1.1 (carbonic anhydrase) inhibitor, an antiglaucoma drug and an ophthalmology drug. It is a sulfonamide and a dichlorobenzene. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NS(=O)(=O)c1cc(Cl)c(Cl)c(S(N)(=O)=O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 120-97-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL17 |
| ChEBI ID | 101085 |
| PubChem CID | 3038 |
| DrugBank | DB01144 |
| UNII ID | VVJ6673MHY (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
CA1
CA1
CA12
CA12
CA4
CA4
Organism
Homo sapiens
Gene name
CA1
Gene synonyms
NCBI Gene ID
Protein name
carbonic anhydrase 1
Protein synonyms
CA-I, CAB, Carbonate dehydratase I, Carbonic anhydrase B, Carbonic anhydrase I, Cyanamide hydratase CA1, epididymis secretory protein Li 11, epididymis secretory sperm binding protein
Uniprot ID
Mouse ortholog
Car1 (12346)
carbonic anhydrase 1 (Q9DC84)
Variants
Clinical Variant
No data
Financial
Keveyis - Strongbridge Biopharma
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Keveyis - Xeris Biopharma Holdings
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 245 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
293 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more